Zheng and colleague found that the integration of CY-09 to the classic gemcitabine treatment dampens tumor resistance by blocking IL-1β/EMT/Wnt/β-catenin signaling pathway in BC [171]. The gene discussed is IL1B; the disease is breast cancer.